title: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
abstract: Although second-generation antipsychotics (SGAs) are used increasingly in children and adolescents, data on the effectiveness and safety in pediatric populations are still sparse. Much of the safety information is derived from studies conducted in adults. This derivation is problematic because children and adolescents are exposed to SGAs during a phase of unparalleled physical and psychologic development that can affect pharmacokinetic and pharmacodynamic drug actions, efficacy, and side-effect patterns. This article presents an overview of SGA-related side effects in children and adolescents and strategies to monitor health outcomes effectively in youngsters receiving SGAs.
authors.affiliation: The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, 75-59 263rd Street, Glen Oaks, NY 11004, USA. ccorrell@lij.edu
authors.forename: Christoph U
authors.initials: CU
authors.lastname: Correll
authors.forename: Julie B
authors.initials: JB
authors.lastname: Penzner
authors.forename: Umesh H
authors.initials: UH
authors.lastname: Parikh
authors.forename: Tahir
authors.initials: T
authors.lastname: Mughal
authors.forename: Tariq
authors.initials: T
authors.lastname: Javed
authors.forename: Maren
authors.initials: M
authors.lastname: Carbon
authors.forename: Anil K
authors.initials: AK
authors.lastname: Malhotra
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D015992:Body Mass Index; D002648:Child; D050171:Dyslipidemias / Q000139:chemically induced; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000139:chemically induced; D011388:Prolactin / Q000378:metabolism; D021641:Recognition, Psychology
chemical_list: D014150:Antipsychotic Agents; D011388:Prolactin